Pfizer's stock has been struggling post-COVID-19 due to challenges like patent cliffs and regulatory shakeups. Despite a low valuation and high dividend yield, uncertainties make holding Pfizer stock challenging.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay